Company* (Country; Symbol) Company (Country; Symbol) Type/Product Area Terms/Details (Date)

Abbott Laboratories (NYSE:ABT) Caprion Proteomics* (Canada) Extended partnership to investigate viable human therapeutic antibody targets for oncology using Caprion's CellCarta tech- nology platform The agreement allows Abbott to retain exclusive rights to 10 targets in lung cancer identified by Caprion for up to two years (6/6)
CombinatoRx Inc. (CRXX) Angiotech Pharmaceuticals Inc. (ANPI) Extended collaboration based upon the successful advance- ment of a number of product candidates in relevant preclinical models The research aims at creating next-generation drug devices and local medicines; the deal was extended to a total of five years, resulting in a $7M payment to CombinatoRx due before Oct. 3 (6/12)
Dyax Corp. (DYAX) Trubion Pharmaceuticals Inc. (TRBN) Expanded research agreement, which covers protein therapeutics and diagnostics discovery Dyax will transfer its phage library to Trubion's facility for use in identifying therapeutic leads to additional targets (5/22)
Repligen Corp. (RGEN) Applied Biosystems (NYSE:ABI) Expanded relationship; entered a new four-year supply agreement for recombinant Protein A Specific terms were not disclosed (6/6)

* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
NYSE = New York Stock Exchange.